<bill session="112" type="h" number="741" updated="2013-07-20T01:16:42-04:00">
  <state datetime="2011-02-16">REFERRED</state>
  <status>
    <introduced datetime="2011-02-16"/>
  </status>
  <introduced datetime="2011-02-16"/>
  <titles>
    <title as="introduced" type="official">To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.</title>
  </titles>
  <sponsor id="400121"/>
  <cosponsors/>
  <actions>
    <action state="REFERRED" datetime="2011-02-16">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2011-02-28">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="unknown" session="112" type="s" number="373"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary>2/16/2011--Introduced.
Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.</summary>
</bill>
